ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)

Diabetes Mellitus, Type 1 Clinical Trial

Official title:

ACCU-CHEK Connect Personal Diabetes Management Study (PDM)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02600845
• Other study ID #: RD002206
• Status: Completed
• Phase: N/A
• First received: November 6, 2015
• Last updated: October 6, 2017
• Start date: December 30, 2015
• Est. completion date: February 20, 2017

Study information

• Verified date: October 2017
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management System over a period of 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 122
• Est. completion date: February 20, 2017
• Est. primary completion date: September 29, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Diagnosis of type 1 or type 2 diabetes for greater than or equal to (>=) 6 months

• Currently using insulin as a component of the diabetes therapy

• Allow and be able to provide self-monitoring of blood glucose (SMBG) data at least 1 month prior to study start

• SMBG frequency as confirmed by site SMBG data download of participants meter(s): Basal insulin treated participants - SMBG >=5 times per week and Multiple dose insulin participants - SMBG >=2 times per day

• Glycosylated hemoglobin (HbA1c) of >=7.5 percentage (per local laboratory obtained less than or equal to [<= 3] months of Baseline)

• Able to read and write in English language

• Currently using a Smartphone and have experience with downloading at minimum one application

• Smartphone compatibility; must be able to download the ACCU-CHEK Connect system application accordingly

• Naive to the ACCU-CHEK Connect system

• Willing to comply with study procedures

Exclusion Criteria:

• Treatment with insulin pump therapy

• Any use of continuous glucose monitoring (CGM) to manage their diabetes during the course of the study

• Visually impaired

• Women who are pregnant, lactating or planning to become pregnant during the study period

• Diagnosed with any clinically significant condition (for example anemia, major organ system disease, infections, psychosis or cognitive impairment)

• Participant requires chronic steroid in adrenal suppressive doses, other immuno-modulatory medication or chemotherapy

• Participant is the investigator or any sub-investigator, general practitioner, practice staff, pharmacist, research assistant or other staff or relative of those directly involved in the conduct of the study and design of the protocol

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Device:
• ACCU-CHEK
ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Hoffmann-La Roche	Roche Diabetes Care GmbH

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment Satisfaction: Diabetes Treatment Satisfaction Questionnaire (DTSQc) Score at Week 24	The Diabetes Treatment Satisfaction Questionnaire for change from Baseline (DTSQc) to study end contains 6 items which can be rated from -3='much worse now' to 3='much better now'). The total score is the sum of the scores of the 6 items and ranges from -18 to 18. A higher score indicates more satisfaction. This questionnaire was administered at the end of the study (Week 24) only.	Week 24
Secondary	Change From Baseline to Week 24 in Diabetes Distress Scale (DDS) Score	Participants rated their level of diabetes distress by answering 17 questions in in the following areas: Regimen-related Distress, Emotional Burden, Diabetes-related Interpersonal Distress and Physician-related Distress (PD) on a 6-point scale: 1=Not a problem to 6=A very serious problem. The Average Total score ranged from 1 (best) to 6 (worst). Results were calculated using a Linear Mixed Model with study group, visit, group-by-visit interaction, baseline DDS, gender, age, and race as fixed effects; and site and subject as random effects. A negative change from Baseline indicated improvement.	Baseline, Week 24
Secondary	Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24	Assessment of HbA1c is an indicator of long-term control of diabetes.	Baseline, Weeks 12 and 24
Secondary	Mean Change From Baseline to Week 24 in Percentage of Glucose Readings in Target Range	Glucose target range was specified as 70-180 milligrams per deciliter (mg/dL).	Baseline, Week 24
Secondary	Change From Baseline to Week 24 in Mean Blood Glucose Level	Blood glucose is a type of sugar in blood and is measured to assess a participant's control of diabetes.	Baseline, Week 24
Secondary	Change From Baseline to Week 24 in Glycemic Variability	Glycemic variability refers to swings in blood glucose levels. Mean glycemic variability is expressed as a standard deviation of blood glucose data. A negative number indicates a decrease in glucose variability. A positive number indicates and increase in glucose variability.	Baseline, Week 24
Secondary	Incidence of Hypoglycemia	A hypoglycemic reading was defined as a glucose value that fell below the 70 mg/dL level. The incidence of hypoglycemia was defined as the number of hypoglycemic readings in the interval divided by the total number of blood glucose checks in the interval.	Baseline, Weeks 12 and 24
Secondary	Number of Participants With Competency in Self-monitoring of Blood Glucose (SMBG) at Week 24	Competency was defined as appropriate response to high and low glucose values.	Week 24
Secondary	Percent of Follow-Up Visits With Sufficient SMBG Data	Sufficient SMBG data is based on the ability of the healthcare provider to make informed decisions regarding therapy adjustments.	Up to Week 24
Secondary	Change From Baseline in the Number of Blood Glucose Checks at Weeks 12 and 24	An increase in the number of blood glucose checks indicates more glycemic control.	Baseline, Weeks 12 and 24
Secondary	Change From Baseline in Mean Daily Self-Monitoring of Blood Glucose (SMBG) Frequency at Weeks 12 and 24	An increase in SMBG frequency indicates more glycemic control. The average number of daily SMBG measurements per interval was calculated based on the total number of blood glucose readings recorded during the study visit interval.	Baseline, Weeks 12 and 24
Secondary	Percentage of Blood Glucose Tagged Data	Tagged data specifies the timing of blood glucose recording and includes: fasting, before breakfast, after breakfast, before lunch, after lunch, before dinner, after dinner, and bedtime. The percentage of blood glucose tagged data per interval was calculated as the total number of tagged blood glucose readings during the interval divided by the total number of readings within the interval.	Weeks 12 and 24